Sex hormone levels and risk of breast cancer with estrogen plus progestin

Journal of the National Cancer Institute

Volumn 105, Issue 19, 2013, Pages 1496-1503

  Farhat, Ghada N ^a,b   Parimi, Neeta ^a   Chlebowski, Rowan T ^c   Manson, Joann E ^d   Anderson, Garnet ^e   Huang, Alison J ^f   Vittinghoff, Eric ^g   Lee, Jennifer S ^h   Lacroix, Andrea Z ^e   Cauley, Jane A ⁱ   Jackson, Rebecca ^j   Grady, Deborah ^f   Lane, Dorothy S ^k   Phillips, Lawrence ^l   Simon, Michael S ^m   Cummings, Steven R ^a  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^b UNIVERSITY OF BALAMAND   (Lebanon)

^c HARBOR UCLA MEDICAL CENTER   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e USA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^j OHIO STATE UNIVERSITY   (United States)

^k STONY BROOK UNIVERSITY   (United States)

^l EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m WAYNE STATE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN; ESTROGEN PLUS PROGESTIN; ESTRONE; ESTRONE SULFATE; GESTAGEN; PROGESTERONE; SEX HORMONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL;

AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; ESTRONE; FEMALE; FOLLOW-UP STUDIES; GONADAL STEROID HORMONES; HUMANS; INCIDENCE; MIDDLE AGED; ODDS RATIO; POSTMENOPAUSE; PROGESTERONE; PROGESTINS; RISK ASSESSMENT; RISK FACTORS; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE; UNITED STATES; WOMEN'S HEALTH;

EID: 84885442041     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djt243     Document Type: Article

References (32)

1. Farhat GN, Cummings SR, Chlebowski RT, et al. Sex hormone levels and risks of estrogen receptor-negative and estrogen receptor-positive breast cancers. J Natl Cancer Inst. 2011;103(7):562-570
2. James RE, Lukanova A, Dossus L, et al. Postmenopausal serum sex steroids and risk of hormone receptor-positive and-negative breast cancer: a nested case-control study. Cancer Prev Res. 2011;4(10):1626-1635
3. Sieri S, Krogh V, Bolelli G, et al. Sex hormone levels, breast cancer risk, and cancer receptor status in postmenopausal women: the ORDET cohort. Cancer Epidemiol Biomarkers Prev. 2009;18(1):169-176
4. Cummings SR, Lee JS, Lui LY, Stone K, Ljung BM, Cauley JA. Sex hormones, risk factors, and risk of estrogen receptor-positive breast cancer in older women: a long-term prospective study. Cancer Epidemiol Biomarkers Prev. 2005;14(5):1047-1051
5. Cummings SR, Tice JA, Bauer S, et al. Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk. J Natl Cancer Inst. 2009;101(6):384-398
6. Key T, Appleby P, Barnes I, et al. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst. 2002;94(8):606-616
7. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women?s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333
8. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women?s Health Initiative randomized trial. JAMA. 2003;289(24):3243-3253
9. Chlebowski RT, Anderson GL, Gass M, et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA. 2010; 304(15):1684-1692
10. Cummings SR, Duong T, Kenyon E, et al. Serum estradiol level and risk of breast cancer during treatment with raloxifene. JAMA. 2002;287(2):216-220
11. Beattie MS, Costantino JP, Cummings SR, et al. Endogenous sex hormones, breast cancer risk, and tamoxifen response: an ancillary study in the NSABP Breast Cancer Prevention Trial (P-1). J Natl Cancer Inst. 2006;98(2):110-115
12. Hays J, Hunt JR, Hubbell FA, et al. The Women?s Health Initiative recruitment methods and results. Ann Epidemiol. 2003;13(9 Suppl):S18-S77
13. National Cancer Institute. About SEER. http://www.seer.cancer.gov/. Accessed August 13, 2013
14. Anderson GL, Manson J, Wallace R, et al. Implementation of the Women?s Health Initiative study design. Ann Epidemiol. 2003;13(9 Suppl):S5-S17
15. Goebelsmann U, Bernstein GS, Gale JA, et al. Serum gonadotropin, testosterone, estradiol and estrone levels prior to and following bilateral vasectomy. In: Lepow R, ed. Vasectomy: Immunologic and Pathophysiologic Effects in Animals and Man. Academic Press: New York: Academic Press; 1979:165
16. Probst-Hensch NM, Ingle SA, Diep AT, et al. Aromatase and breast cancer susceptibility. Endocr Relat Cancer. 1999;6(2):165-173
17. Scott JZ, Stanczyk FZ, Goebelsmann U, et al. A double-antibody radioimmunoassay for serum progesterone using progesterone-3-(O-carboxymethyl) oximino-[125I]-iodo-histamine as radioligand. Steroids. 1978;31(3):393-405
18. Slater CC, Hodis HN, Mack WJ, Shoupe D, Paulson RJ, Stanczyk FZ. Markedly elevated levels of estrone sulfate after long-term oral, but not transdermal, administration of estradiol in postmenopausal women. Menopause 2001;8(3):200-203
19. Sodergard R, Bäckström T, Shanbhag V, Carstensen H. Calculation of free and bound fractions of testosterone and estradiol-17 beta to human plasma proteins at body temperature. J Steroid Biochem. 1982;16(6):801-810
20. Vermeulen AL, Verdonck JM, Kaufman L. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab. 1999;84(10):3666-3672
21. Rinaldi S, Geay A, Déchaud H, et al. Validity of free testosterone and free estradiol determinations in serum samples from postmenopausal women by theoretical calculations. Cancer Epidemiol Biomarkers Prev. 2002;11(10 Pt 1):1065-1071
22. Heiss G, Wallace R, Anderson GL, et al. Health risks and benefits 3 years after stopping randomized treatment with estrogen plus progestin. JAMA. 2008;299(9):1036-1045
23. Cauley JA, LaCroiz AZ, Robbins JA, et al. Baseline serum estradiol and fracture reduction during treatment with hormone therapy: the Women?s Health Initiative randomized trial. Osteoporos Int. 2010;21(1):167-177
24. Stanczyk FZ, Jurow J, Hsing AW. Limitations of direct immunoassays for measuring circulating estradiol levels in postmenopausal women and men in epidemiologic studies. Cancer Epidemiol Biomarkers Prev. 2010;19(4):903-906
25. Tworoger SS, Missmer SA, Barbieri RL, et al. Plasma sex hormone concentrations and subsequent risk of breast cancer among women using postmenopausal hormones. J Natl Cancer Inst. 2005;97(8):595-602
26. Edlefsen KL, Jackson RD, Prentice RL, et al. The effects of postmenopausal hormone therapy on serum estrogen, progesterone, and sex hormonebinding globulin levels in healthy postmenopausal women. Menopause. 2010;17(3):622-629
27. Lambrinoudaki I, Armeni E, Rizos D. et al. Sex hormones in postmenopausal women receiving low-dose hormone therapy: the effect of BMI. Obesity. 2011;19(5):988-993
28. Endogenous Hormones and Breast Cancer Collaborative Group. Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. Br J Cancer. 2011;105(5):709-722
29. Chlebowski RT, Anderson GL. Changing concepts: menopausal hormone therapy and breast cancer. J Natl Cancer Inst. 2012;104(7):517-527
30. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women?s Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701-1712
31. Stefanick ML, Anderson GL, Margolis KL, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA. 2006;295(14):647-657
32. Lacroix AZ, Chlebowski RT, Manson JE, et al. Health risks and benefits 5 years after stopping randomized treatment with conjugated equine estrogens in postmenopausal women with prior hysterectomy. JAMA. 2011;305(13):1305-1314